{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:32:31Z","timestamp":1790332351974,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"CIBER \u2013 Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tenofovir alafenamide (TAF) has replaced tenofovir disoproxil fumarate (TDF) in many clinical settings. However, concerns remain about potential metabolic complications of TAF. We aimed to evaluate changes in weight, laboratory markers, and metabolic-related clinical events after replacing TDF with TAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Multicenter prospective cohort study in the Spanish CoRIS cohort. We included virologically suppressed adults with human immunodeficiency virus (HIV) receiving TDF for more than 12 months who either switched to TAF or maintained TDF, with no changes in the core agent. Participants were matched by propensity score. We fitted generalized equation models to assess changes in weight, blood lipids, and hepatic steatosis index, and to compare the incidence of diabetes, hypertension, and lipid-lowering drug use after 144 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 1446 participants were matched in each group. Median age was 38 years, 85% were male, mean weight at baseline was 73 kg. Participants who switched to TAF had a mean weight increase of +0.5 kg at 144 weeks over those who maintained TDF, with no difference in the occurrence of overweight or obesity. Individuals who switched to TAF had a significant increase in total cholesterol (+7.9 mg\/dL) and triglycerides (+11.2 mg\/dL), with no differences in the total cholesterol-high-density lipoprotein (HDL) ratio. However, no increased incidence of diabetes, hypertension, or lipid-lowering drug use was observed after the follow-up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Switching from TDF to TAF is associated with modest weight gain and increases in total cholesterol and triglycerides, without an impact on the incidence of obesity or metabolic-related clinical events, in this Spanish cohort with a majority White male population.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciac621","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T07:09:02Z","timestamp":1659078542000},"page":"e652-e660","source":"Crossref","is-referenced-by-count":28,"title":["Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study"],"prefix":"10.1093","volume":"76","author":[{"given":"Javier","family":"Mart\u00ednez-Sanz","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Serrano-Villar","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Muriel","sequence":"additional","affiliation":[{"name":"Clinical Biostatistic Unit, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid , Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"University of Alcal\u00e1 , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio J","family":"Garc\u00eda Fraile","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Department of Internal Medicine, Hospital Universitario de La Princesa , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Orviz","sequence":"additional","affiliation":[{"name":"Centro Sanitario Sandoval, Hospital Cl\u00ednico San Carlos, IdISSC , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Mena de Cea","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Complejo Hospitalario Universitario a Coru\u00f1a (CHUAC) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni A","family":"Campins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Infectious Diseases, Hospital Universitario Son Espases , Palma , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"University of Alcal\u00e1 , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"2023020817074617800_ciac621-B1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV cohort study","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"2023020817074617800_ciac621-B2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"2023020817074617800_ciac621-B4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 Recommendations of the International Antiviral Society-USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2023020817074617800_ciac621-B5"},{"key":"2023020817074617800_ciac621-B6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2023020817074617800_ciac621-B7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/COH.0000000000000379","article-title":"Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide","volume":"12","author":"Gotham","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2023020817074617800_ciac621-B9","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/cid\/civ192","article-title":"Weight change after antiretroviral therapy and mortality","volume":"60","author":"Yuh","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B10","doi-asserted-by":"crossref","first-page":"1138S","DOI":"10.3945\/ajcn.2010.28608D","article-title":"Nutritional aspects of HIV-associated wasting in sub-Saharan Africa","volume":"91","author":"Koethe","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"2023020817074617800_ciac621-B11","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"2023020817074617800_ciac621-B13","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. Cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023020817074617800_ciac621-B14","doi-asserted-by":"crossref","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","article-title":"Lipid changes after switch from TDF to TAF in the OPERA cohort: lDL cholesterol and triglycerides","volume":"9","author":"Mallon","year":"2022","journal-title":"Open forum Infect Dis"},{"key":"2023020817074617800_ciac621-B15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"2023020817074617800_ciac621-B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cid\/ciy083","article-title":"Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine","volume":"67","author":"Glidden D","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B17","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1097\/QAD.0000000000003083","article-title":"Is tenofovir disoproxil fumarate associated with weight loss?","volume":"35","author":"Shah","year":"2021","journal-title":"AIDS"},{"key":"2023020817074617800_ciac621-B18"},{"key":"2023020817074617800_ciac621-B19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eimc.2011.06.002","article-title":"The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up","volume":"29","author":"Sobrino-Vegas","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2023020817074617800_ciac621-B20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00394-018-1677-2","article-title":"Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children","volume":"58","author":"Bonafini","year":"2019","journal-title":"Eur J Nutr"},{"key":"2023020817074617800_ciac621-B21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2023020817074617800_ciac621-B22"},{"key":"2023020817074617800_ciac621-B23","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2023020817074617800_ciac621-B24","doi-asserted-by":"crossref","first-page":"e25732","DOI":"10.1002\/jia2.25732","article-title":"Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study","volume":"24","author":"Mart\u00ednez-Sanz","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023020817074617800_ciac621-B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2023020817074617800_ciac621-B26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cid\/ciz439","article-title":"Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077","volume":"70","author":"Landovitz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B27","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine (DTG\/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B28","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1097\/QAD.0000000000003092","article-title":"Weight gain stopping\/switch rules for antiretroviral clinical trials","volume":"35","author":"Francois Venter","year":"2021","journal-title":"AIDS"},{"key":"2023020817074617800_ciac621-B29","doi-asserted-by":"crossref","first-page":"e10106","DOI":"10.1371\/journal.pone.0010106","article-title":"Increasing rates of obesity among HIV-infected persons during the HIV epidemic","volume":"5","author":"Crum-Cianflone","year":"2010","journal-title":"PLoS One"},{"key":"2023020817074617800_ciac621-B30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","article-title":"Brief Report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults","volume":"75","author":"Raffi","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023020817074617800_ciac621-B31","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV"},{"key":"2023020817074617800_ciac621-B32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","article-title":"Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers","volume":"46","author":"Shaheen","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2023020817074617800_ciac621-B34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/cid\/ciw285","article-title":"Higher prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is associated with changes in body composition and prior stavudine exposure","volume":"63","author":"van Zoest","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023020817074617800_ciac621-B35","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1097\/HJH.0b013e32830ef5fb","article-title":"Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy","volume":"26","author":"Baekken","year":"2008","journal-title":"J Hypertens"},{"key":"2023020817074617800_ciac621-B36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1089\/apc.2019.0236","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting","volume":"33","author":"Kauppinen","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"2023020817074617800_ciac621-B37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000002541","article-title":"Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV","volume":"34","author":"Lacey","year":"2020","journal-title":"AIDS"},{"key":"2023020817074617800_ciac621-B38","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","article-title":"Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes","volume":"35","author":"McCann","year":"2021","journal-title":"AIDS"},{"key":"2023020817074617800_ciac621-B39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10742-012-0090-1","article-title":"Bias and variance trade-offs when combining propensity score weighting and regression: with an application to HIV status and homeless men","volume":"12","author":"Golinelli","year":"2012","journal-title":"Health Serv Outcomes Res Methodol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac621\/45473643\/ciac621.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e652\/49125024\/ciac621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e652\/49125024\/ciac621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T03:22:03Z","timestamp":1700882523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/3\/e652\/6651472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,29]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac621","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,29]]}}}